COSMOS Pharmaceutical Corporation
CSMYF · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $259 | $246 | $244 |
| % Growth | -99.3% | 5.2% | 0.9% | – |
| Cost of Goods Sold | $1 | $205 | $193 | $193 |
| Gross Profit | $0 | $54 | $53 | $52 |
| % Margin | 21% | 20.9% | 21.6% | 21.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $25 | $42 | $43 |
| Sales & Mktg Exp. | $0 | $2 | $0 | $0 |
| Other Operating Expenses | $0 | $21 | -$0 | $0 |
| Operating Expenses | $0 | $45 | $42 | $43 |
| Operating Income | $0 | $9 | $11 | $9 |
| % Margin | 4.3% | 3.4% | 4.6% | 3.6% |
| Other Income/Exp. Net | $0 | $0 | $0 | $1 |
| Pre-Tax Income | $0 | $9 | $12 | $9 |
| Tax Expense | $0 | $1 | $4 | $3 |
| Net Income | $0 | $9 | $8 | $6 |
| % Margin | 3% | 3.3% | 3.2% | 2.6% |
| EPS | 0.7 | 108.95 | 99.86 | 79.3 |
| % Growth | -99.4% | 9.1% | 25.9% | – |
| EPS Diluted | 0.7 | 108.95 | 99.86 | 79.3 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $6 | $5 | $5 |
| EBITDA | $0 | $15 | $16 | $14 |
| % Margin | 6.6% | 5.9% | 6.5% | 5.8% |